Literature DB >> 164280

The specific cytotoxic effects of daunomycin conjugated to antitumor antibodies.

R Levy, E Hurwitz, R Maron, R Arnon, M Sela.   

Abstract

Daunomycin was covalently bound to immunoglobulins by periodate oxidation as described in the preceding paper. Conjugates were prepared with immunoglobulins directed against either of two mouse lymphoid tumors or with nonspecific immunoglobulins. These conjugates were tested for their toxic effects on various tumor target cells as measured either by their inhibition of RNA synthesis or by their reduction of the growth of the tumor cells after transplantation. We found that the drug preferentially affected the target cells that the antibody to which it was attached could recognize. These daunomycin-antibody conjugates are therefore sufficiently toxic and selective in their effects to be potentially useful in in vivo therapeutic studies.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 164280

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Profile of Ronald Levy. Interview by Phillip Downey.

Authors:  Ronald Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

2.  Probing into the realm of proteins and immunity.

Authors:  M Sela
Journal:  Protein Sci       Date:  1998-07       Impact factor: 6.725

Review 3.  A brief personal history of cancer immunotherapy at Stanford: if these walls could talk….

Authors:  Ron Levy
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

Review 4.  Antibodies as specific carriers for chemotherapeutic agents.

Authors:  F H Lee; K M Hwang
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

5.  Selective killing of T lymphocytes by phototoxic liposomes.

Authors:  S Yemul; C Berger; A Estabrook; S Suarez; R Edelson; H Bayley
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

6.  Drug targeting by drug entrapment into ultrafine compartments as carriers.

Authors:  P Speiser
Journal:  Appl Biochem Biotechnol       Date:  1984       Impact factor: 2.926

7.  Experimental studies on specific immunotherapy in nasopharyngeal carcinoma (NPC).

Authors:  W Arnold; K H Vosteen
Journal:  Arch Otorhinolaryngol       Date:  1980

Review 8.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

9.  Inhibition of Epstein-Barr-virus-transformed human chronic lymphocytic leukaemic B cells with monoclonal-antibody-adriamycin (doxorubicin) conjugates.

Authors:  Z Zhu; J Kralovec; T Ghose; M Mammen
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

Review 10.  Oncostatic-antibody complexes in chemotherapy.

Authors:  H F Dullens; R A De Weger
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.